<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HCA5A992AB92D4F0E88198F06C8C999FA" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 6807 IH: Knock Out Cancer Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-12-14</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 6807</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20231214">December 14, 2023</action-date><action-desc><sponsor name-id="F000466">Mr. Fitzpatrick</sponsor> (for himself and <cosponsor name-id="D000624">Mrs. Dingell</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HAP00">Committee on Appropriations</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.</official-title></form><legis-body id="H563C4CEE845847BC88DA87D85642BB60" style="OLC"><section id="H819460931E1A4048BDDAD09F32078157" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Knock Out Cancer Act</short-title></quote> or the <quote><short-title>KO Cancer Act</short-title></quote>.</text></section><section id="HA1308390A4F54A44BEC8A61E78497B25"><enum>2.</enum><header>Increasing NCI budget for cancer research</header><text display-inline="no-display-inline">To conduct or support cancer research, there is hereby appropriated, for each of fiscal years 2024 through 2028, to the National Cancer Institute, out of amounts in the Treasury not otherwise appropriated, an amount that is equal to 25 percent of the total amount appropriated to the National Cancer Institute for fiscal year 2022, to remain available until expended. Amounts appropriated pursuant to the preceding sentence shall be in addition to amounts otherwise made available to the National Cancer Institute.</text></section><section id="H7A2FDCEA86CF4388B57568D069922B95" commented="no"><enum>3.</enum><header>Report to Congress on cancer drug shortages</header><subsection id="H2E4B1F0323CB4C31BB1D450410CEEFD1" commented="no"><enum>(a)</enum><header>Study</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, in collaboration with such other agencies as the Secretary deems necessary, shall study the reasons for cancer drug shortages, including—</text><paragraph id="H4CBABCE7CE1E40808C47582B0D3F4D83" commented="no"><enum>(1)</enum><text>economic reasons;</text></paragraph><paragraph id="HAE545816592F402DBFAAAB9408EEA6FF"><enum>(2)</enum><text>supply chain failures;</text></paragraph><paragraph id="H8AB12B0F710F4D5D849D11D593F1276A" commented="no"><enum>(3)</enum><text>delays and other complications relating to—</text><subparagraph id="H3B9266FAF92341C59BB4B292FF1C1944" commented="no"><enum>(A)</enum><text>the development of cancer drugs; and</text></subparagraph><subparagraph id="H90C047295C2946BBBE77CEECA23B279F" commented="no"><enum>(B)</enum><text>the approval of such drugs by the Food and Drug Administration; and</text></subparagraph></paragraph><paragraph id="H87C0DB8CD61E4481B233C1A91A3DAE92" commented="no"><enum>(4)</enum><text>insufficient generic drugs and biosimilar biological products.</text></paragraph></subsection><subsection id="H64DAFAD4077D483D8734E55882B10E1E" commented="no"><enum>(b)</enum><header>Report</header><paragraph id="H4822AEF134484696B8E3EE404B6AEB66"><enum>(1)</enum><header>In general</header><text>Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall complete the study under subsection (a) and submit a report to the appropriate committees of the Congress on the results of such study.</text></paragraph><paragraph id="H65BB1F6A138C4C39AA95A30F7A0AAA7D"><enum>(2)</enum><header>Recommendations</header><text>The report under paragraph (1) shall include recommendations for addressing the reasons for cancer drug shortages.</text></paragraph></subsection></section></legis-body></bill> 

